Dr. Tolaney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street Yaw 7604
Massachusetts General Hospital
Boston, MA 02114Phone+1 617-726-2782Fax+1 617-394-3012
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
- Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
- University of California San Francisco School of MedicineClass of 2002
Certifications & Licensure
- FL State Medical License 2022 - Present
- MA State Medical License 2005 - 2026
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Bicalutamide in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2007 Mar 23
- Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01
- Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Start of enrollment: 2011 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.Brooke M Felsheim, Aranzazu Fernandez-Martinez, Cheng Fan, Adam D Pfefferle, Michele C Hayward
NPJ Breast Cancer. 2025-03-08 - Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases.Thomas Grinda, Stefania Morganti, Liangge Hsu, Tae-Kyung Yoo, Ross J Kusmick
NPJ Breast Cancer. 2025-03-05 - CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.Erika P Hamilton, Sibylle Loibl, Thomas Bachelot, Michael Gnant, Naoki Niikura
Future Oncology. 2025-03-01
Journal Articles
- Effect of Eribulin with or Without Pembrolizumab on Progression-Free Survival for Patients with Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerSara M Tolaney, Gerburg Wulf, Laura Spring, Beth Overmoyer, Ann H Partridge, Eric P Winer, Ian E Krop, JAMA Oncology
Lectures
- Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).2019 ASCO Annual Meeting - 6/1/2019
- New Frontiers in HER2-Positive Breast Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Press Mentions
- Trial Data Helped Guide Treatment of Stage II-III Triple-Negative Breast CancerDecember 11th, 2024
- When or Whether to Give Immunotherapy in Early Breast CancerNovember 19th, 2024
- INAVO120 Trial Tests Inavolisib in HR+, HER2-, PIK3C-Alpha-Mutated DiseaseOctober 30th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: